IMCIVREE
IMCIVREE (setmelanotide) is a daily subcutaneous injection approved for treating severe, early-onset obesity caused by rare genetic defects in the melanocortin pathway — specifically POMC, PCSK1, or LEPR mutations, and Bardet-Biedl syndrome. The drug is a melanocortin-4 receptor (MC4R) agonist that bypasses the broken signaling proteins and directly activates the hypothalamic receptor that controls hunger and energy expenditure. Patients with these mutations experience extreme, treatment-resistant obesity from childhood because their brains cannot generate or respond to satiety signals; IMCIVREE is the only approved pharmacological option for these ultra-rare syndromes.
Upcoming catalysts
Programs
Bardet-Biedl Syndrome Obesity
Bardet-Biedl syndrome (BBS) is a rare genetic disorder in which ciliary gene mutations impair hypothalamic melanocortin signaling, causing severe childhood-onset obesity that is unresponsive to diet and conventional pharmacotherapy; no approved treatment existed before IMCIVREE. IMCIVREE is approved for BBS obesity in patients aged 6 and older; this NDA seeks label expansion to the 2–5 age group, with an August 2026 PDUFA following an earlier FDA extension for a CMC amendment.